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101* Inhaled tobramycin nebulizer solution for treatment of early
Pseudomonas aeruginosa infection: the ELITE study
F. Ratjen1, S. Stenglein2, A. Munck3. 1Hospital for Sick Children, Toronto, ON,
Canada; 2Novartis Pharma AG, Basel, Switzerland; 3Hospital Robert Debre,
Paris, France
The beneﬁt of early antibiotic intervention in treating P. aeruginosa in patients with
cystic ﬁbrosis (CF) is increasingly acknowledged. However, the effect of different
treatment periods in this early intervention is unclear.
In the open-label, randomized, multicentre ELITE (EarLy Inhaled Tobramycin for
Eradication) study, CF patients 6 months of age with early P. aeruginosa infection
were treated twice daily with tobramycin nebulizer solution (TNS; 300mg in 5ml)
for 28 or 56 days and followed up for 27 months. The primary objective was to
determine the median time to recurrence of any strain of P. aeruginosa. Secondary
objectives were (a) assessment of the proportion of patients free of P. aeruginosa
1 month after completion of TNS treatment and (b) a safety evaluation of TNS.
All patients were initially given TNS for 28 days. Eligible patients were then
randomized 1:1 either to stop TNS treatment or to receive a further 28 days of treat-
ment. The study recruited 123 patients at 21 European CF centres; 35 patients were
not randomized due to the presence of P. aeruginosa antibodies at baseline. Of the
88 randomized patients, 46 received 28 days and 42 received 56 days of treatment.
Genotyping of P. aeruginosa isolates obtained at baseline and on recurrence was
conducted using random ampliﬁed polymorphic DNA polymerase chain reaction
and pulsed-ﬁeld gel electrophoresis for similar strains. Safety monitoring assessed
treatment-emergent adverse events, serum tobramycin levels, renal function, and
audiometry. Study recruitment was completed in November 2005, and the last
patient completed follow-up in January 2008. Final results of the study will be
presented at the meeting.
Supported by: Novartis Pharma AG.
102* A randomized placebo-controlled study of nebulized liposomal
amikacin (Arikace™) in the treatment of cystic ﬁbrosis patients
with chronic Pseudomonas aeruginosa lung infection
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Objective: Arikace™ is a sustained-release liposome formulation of amikacin for
inhalation being developed for the treatment of P. aeruginosa (Pa) infection in
CF patients (pts). The primary objective of this study was to evaluate the effects of
28-day (d) exposure of Arikace™.
Methods: This is a Phase2a study conducted in 15centers in Europe. Patients were
stratiﬁed by baseline FEV1(%pred) and randomized 2:1 to Arikace™ or placebo
(1.5% NaCl). Cohort1 received 280mg and Cohort2, 560mg of active drug or
placebo for 28d by inhalation with PARIeFlow® nebulizer, and were followed for
28d. Safety; pharmacokinetics; Pa sputum density; Quality of Life (CFQ-R) and
exacerbation rate were evaluated weekly during the study period of 56d.
Results: 66pts were enrolled. 32 Cohort1 pts have completed study:10adults;12pts
aged 13−18 yr;10pts aged 6−12 yr. Baseline FEV1(%pred) was 40−75% in 19pts
and >75% in 13pts. A review of safety and efﬁcacy data by the DSMB recom-
mended enrollment in Cohort2, and 34pts have enrolled:13 adults;13 pts aged
13−18 yr; 8pts aged 6−12 yr. Baseline FEV1(%pred) was 40−75% in 24pts and
>75% in 10pts. All pts in Cohort2 have received >17d of treatment and 29pts have
completed 28d of treatment. Final study data available in April for submission to
ECFS.
Conclusion: Arikace™ given once daily for 28d at a dose of 280mg was well
tolerated in CFpts. To date 29pts in Cohort2 (560mg) have completed treatment
and others are being evaluated. Baseline characteristics and clinical parameters of
pts enrolled in this randomized, placebo-controlled study of Arikace™ for inhalation
provides an initial proﬁle of the population that may beneﬁt from this treatment.
103* Pharmacokinetics of ciproﬂoxacin PulmoSphere® inhalational
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Introduction: Ciproﬂoxacin has proven anti-pseudomonal activity. An inhaled
formulation – Ciproﬂoxacin PulmoSphere® Inhalational Powder (CPIP) has been
developed to maximise bactericidal activity in lung endothelia of cystic ﬁbrosis
(CF) patients.
Methods: In a Phase I single-centre, randomised, single-blind placebo-controlled
study of healthy male volunteers, subjects inhaled a single 50mg dose of CPIP
(32.5mg ciproﬂoxacin betaine) followed by 50mg placebo. Vital signs, electrocar-
diogram, lung function (total speciﬁc resistance, thoracic gas volume and FEV1)
and adverse events (AE) were assessed. Systemic absorption was measured in blood
and urine. PK parameters were calculated from plasma concentration vs time data.
A physiological PK model of inhalation administration was used to estimate CPIP
deposition in the lungs. A further study in CF patients is on-going.
Results: CPIP was well tolerated with no clinically relevant AE and no clinically
relevant changes in vital signs, ECG outputs or lung function. Compared with his-
toric data for a single IV/PO dose (e.g. Cmax 3−5mg/L), a minimal total systemic
exposure was seen (AUC 0.354mg*h/L, median tmax 0.6 h; Cmax 0.06mg/L).
Terminal half life (9.5 h), clearance (91.7L/h) and volume of distribution (1262L)
data indicate that CPIP was delivered effectively to the lungs. PK modelling showed
~20% of the inhaled dose was deposited in the trachea/bronchi.
Conclusion: In healthy male subjects, inhaled CPIP is well tolerated, has minimal
systemic exposure and is delivered in an active form to the lungs.
Supported by: Bayer HealthCare AG.
104 Single-dose pharmacokinetics of aerosol MP-376 (levoﬂoxacin
solution for inhalation) in cystic ﬁbrosis patients:
PK−PD implications
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Objective: Pulmonary delivery of anti-infectives provides the potential to attain
PK-PD indices in the lung that exceed those which can be achieved with systemic
dosing. MP-376 is a novel formulation of levoﬂoxacin (LVX) that enables safe,
rapid delivery, and provides taste masking. This analysis compares LVX sputum
and serum pharmacokinetics following aerosol MP-376 with an oral 750mg LVX
dose.
Methods: Eight stable CF patients were enrolled in a single ascending dose study
of MP-376 loaded doses of 78, 175, and 260mg using the PARI eFlow nebulizer.
In a separate group of 8 CF patients, oral LVX 750mg was administered. Serum
and sputum samples were assayed for LVX concentration using HPLC.
Results: The mean LVX Cmax in the sputum following aerosol MP-376 doses of
78, 175, and 260mg, or oral LVX were 388, 714, 1 112, and 9mg/L, respectively.
Mean sputum LVX AUCs following aerosol MP-376 doses or oral LVX were 851,
656, 1 448, and 93mg-h/L, respectively. Mean serum LVX AUCs for aerosol MP-
376 or oral LVX were 2.0, 4.5, 6.5, and 77mg-h/L, respectively. Aerosol doses of
MP-376 were well-tolerated, with no drug-related serious adverse effects.
Conclusions: Aerosol administration of MP-376 results in markedly higher LVX
exposures in sputum compared to maximum oral doses, thus increasing key PK-PD
indices for antibacterial effects. Serum LVX levels are at least 10-fold lower with
aerosol administration of MP-376 compared to oral doses. Multiple-dose safety and
efﬁcacy studies of MP-376 in CF patients are in progress.
